AxioMed received approval under the CE Mark for their viscoelastic cervical disc device. Full global launch will occur within 2019.
Last month, parent company KICVentures announced that it seeks funding to prepare its spine portfolio companies, AxioMed and NanoFUSE Biologics, to be acquisition targets in the next three to five years. Assets include AxioMed Freedom cervical and lumbar disc replacements and NanoFUSE bioactive glass.
AxioMed received approval under the CE Mark for their viscoelastic cervical disc device. Full global launch will occur within 2019.
Last month, parent company KICVentures announced that it seeks funding to prepare its spine portfolio companies, AxioMed and NanoFUSE Biologics, to be acquisition targets in the next...
AxioMed received approval under the CE Mark for their viscoelastic cervical disc device. Full global launch will occur within 2019.
Last month, parent company KICVentures announced that it seeks funding to prepare its spine portfolio companies, AxioMed and NanoFUSE Biologics, to be acquisition targets in the next three to five years. Assets include AxioMed Freedom cervical and lumbar disc replacements and NanoFUSE bioactive glass.
Copy to clipboard 
